ATE251905T1 - Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien - Google Patents

Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien

Info

Publication number
ATE251905T1
ATE251905T1 AT00974804T AT00974804T ATE251905T1 AT E251905 T1 ATE251905 T1 AT E251905T1 AT 00974804 T AT00974804 T AT 00974804T AT 00974804 T AT00974804 T AT 00974804T AT E251905 T1 ATE251905 T1 AT E251905T1
Authority
AT
Austria
Prior art keywords
treatment
ubiquinone
prevention
pathologies
occular
Prior art date
Application number
AT00974804T
Other languages
English (en)
Inventor
Rosario Brancato
Sergio Capaccioli
Marco Fabrizio Saettone
Nicola Schiavone
Original Assignee
Simonelli Giuseppe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simonelli Giuseppe filed Critical Simonelli Giuseppe
Application granted granted Critical
Publication of ATE251905T1 publication Critical patent/ATE251905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00974804T 1999-11-25 2000-10-30 Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien ATE251905T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000719A IT1307281B1 (it) 1999-11-25 1999-11-25 Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
PCT/IT2000/000434 WO2001037851A2 (en) 1999-11-25 2000-10-30 Use of ubiquinone q10 for the local treatment and prevention of post-surgical ophthalmologic pathologies

Publications (1)

Publication Number Publication Date
ATE251905T1 true ATE251905T1 (de) 2003-11-15

Family

ID=11407065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00974804T ATE251905T1 (de) 1999-11-25 2000-10-30 Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien

Country Status (8)

Country Link
US (1) US6787572B2 (de)
EP (1) EP1231909B1 (de)
AT (1) ATE251905T1 (de)
AU (1) AU1301001A (de)
DE (1) DE60005992T2 (de)
ES (1) ES2208434T3 (de)
IT (1) IT1307281B1 (de)
WO (1) WO2001037851A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
PT1421974E (pt) * 2002-06-10 2007-03-30 Dmg Italia Srl Solução oftálmica contendo carboximetilbeta-1,3-glucano
ITRM20030153A1 (it) 2003-04-03 2004-10-04 Exall S R L Formulazione idrosolubile contenente ubichinone per uso oftalmico.
RS52735B (en) 2005-07-08 2013-08-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
JP2009536215A (ja) * 2006-05-02 2009-10-08 ユニバーシティ オブ マイアミ 局所コエンザイムｑ１０製剤、及び疼痛、疲労、並びに創傷の治療
US9119827B2 (en) * 2009-06-30 2015-09-01 Lion Corporation Ophthalmic composition
ITVA20100044A1 (it) * 2010-05-20 2011-11-21 Ciro Caruso Soluzione oftalmica per proteggere strutture interne del globo oculare da raggi uv-a o per il trattamento del cheratocono con tecnica di cross-linking trans-epiteliale
ES2441227T3 (es) * 2009-07-27 2014-02-03 Salvatore Troisi Disolución oftálmica para la protección de las estructuras internas del globo ocular frente a los rayos UV-A o para el tratamiento del queratocono con una técnica de entrecruzamiento transepitelial
JP7173992B2 (ja) 2017-05-17 2022-11-17 バーグ エルエルシー 表皮水疱症の治療および防止におけるコエンザイムｑ１０製剤の使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5947202A (ja) * 1982-09-10 1984-03-16 Zeria Shinyaku Kogyo Kk 補酵素Ｑ↓１↓０のメチル化−β−シクロデキストリン包接体及びその製造方法
DE4410238A1 (de) * 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
ES2283002T3 (es) * 1995-06-07 2007-10-16 The Howard Foundation Carotenoides farmaceuticamente activos.
JP4426091B2 (ja) * 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
AU3930600A (en) * 1999-03-30 2000-10-16 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof

Also Published As

Publication number Publication date
ITRM990719A0 (it) 1999-11-25
ITRM990719A1 (it) 2001-05-25
EP1231909A2 (de) 2002-08-21
DE60005992D1 (de) 2003-11-20
AU1301001A (en) 2001-06-04
EP1231909B1 (de) 2003-10-15
WO2001037851A3 (en) 2002-03-21
US20030236239A1 (en) 2003-12-25
DE60005992T2 (de) 2004-07-22
WO2001037851A2 (en) 2001-05-31
US6787572B2 (en) 2004-09-07
ES2208434T3 (es) 2004-06-16
IT1307281B1 (it) 2001-10-30

Similar Documents

Publication Publication Date Title
JP2010507686A5 (de)
DE69930252D1 (de) Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
DE701443T1 (de) Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
ATE251905T1 (de) Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien
CN107072203B (zh) 用黑色素及其类似物、前体和衍生物治疗和预防眼部疾病、障碍和病症的方法
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
CY1106140T1 (el) Χρηση νευρικου αυξητικου παραγοντα για την παρασκευη ενος φαρμακου για την θepαπεια παθολογικων καταστασεων του ενδοφθαλμικου ιστου
CY1108572T1 (el) Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο
PT1244438E (pt) Utilizacao de antagonistas dos receptores beta-adrenergicos para o fabrico de um medicamento destinado ao tratamento de perturbacoes da retina externa
DE69614553T2 (de) Aromatische carbonsaürediamide mit antigastrin wirkung, ihre herstellung und pharmazeutische verwendung
DE60000736D1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
ES2234428B1 (es) Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
Naik et al. 8-Methoxypsoralen-lnduced Nail Pigmentation.
AU643772B2 (en) Use of hexetidine or its derivatives or salts for the preparation of a pharmaceutical composition for ophthalmological use
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
Crawford Cortisone in glaucoma secondary to uveitis
Weissman Risk of corneal infection and extended wear of contact lenses.
Schwab Nonsteroidal eye drops for ocular allergy.
IT202100021659A1 (it) Composizione topica e suo uso per il trattamento nasale della rinite
KR890001555A (ko) 요산 배설용 조성물
Odeneal Thermophore Therapy of a Case of Keratitis
Aragona et al. 3425 Effect of the topical administration of diclofenac sodium and indomethacin on corneal sensitivity in normal subjects

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties